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Abstract
Background: African American (AA) colon cancer patients have a worse prognosis than Caucasian (CA) colon
cancer patients, however, reasons for this disparity are not well understood. To determine if tumor biology might
contribute to differential prognosis, we measured recurrence risk and gene expression using the Oncotype DX®
Colon Cancer Assay (12-gene assay) and compared the Recurrence Score results and gene expression profiles
between AA patients and CA patients with stage II colon cancer.
Methods: We retrieved demographic, clinical, and archived tumor tissues from stage II colon cancer patients at four
institutions. The 12-gene assay and mismatch repair (MMR) status were performed by Genomic Health (Redwood
City, California). Student’s t-test and the Wilcoxon rank sum test were used to compare Recurrence Score data and
gene expression data from AA and CA patients (SAS Enterprise Guide 5.1).
Results: Samples from 122 AA and 122 CA patients were analyzed. There were 118 women (63 AA, 55 CA) and 126
men (59 AA, 67 CA). Median age was 66 years for AA patients and 68 for CA patients. Age, gender, year of surgery,
pathologic T-stage, tumor location, the number of lymph nodes examined, lymphovascular invasion, and MMR
status were not significantly different between groups (p = 0.93). The mean Recurrence Score result for AA patients
(27.9 ± 12.8) and CA patients (28.1 ± 11.8) was not significantly different and the proportions of patients with high
Recurrence Score values (≥41) were similar between the groups (17/122 AA; 15/122 CA). None of the gene expression
variables, either single genes or gene groups (cell cycle group, stromal group, BGN1, FAP, INHBA1, Ki67, MYBL2, cMYC
and GADD45B), was significantly different between the racial groups. After controlling for clinical and pathologic
covariates, the means and distributions of Recurrence Score results and gene expression profiles showed no
statistically significant difference between patient groups.
Conclusion: The distribution of Recurrence Score results and gene expression data was similar in a cohort of AA
and CA patients with stage II colon cancer and similar clinical characteristics, suggesting that tumor biology, as
represented by the 12-gene assay, did not differ between patient groups.
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At a glance
 Tumor biology as reflected in differential gene
expression may contribute to differential outcomes
for African-American patients as compared to
Caucasian colon cancer patients.
 A cohort of patients well balanced for clinical and
demographic factors was selected for gene expression
testing using the Oncotype DX colon cancer assay as
a measure of tumor biology.
 The distribution of Recurrence Score results for
African-American patients (n = 122) was not
significantly different than that of Caucasian
patients (n = 122).
 Expression of single genes or gene groups (cell cycle
group, stromal group, BGN1, FAP, INHBA1, Ki67,
MYBL2, cMYC and GADD45B) also did not differ
significantly between ethnic groups.
 Although differences in outcomes have been observed
between AA and CA patients, this study found no
difference in tumor biology as represented by the
12-gene assay when no differences in demographic or
clinical factors were present.
Background
Racial disparities in the outcomes of many cancers are a
well-recognized phenomenon. Although the survival of
patients with colorectal cancer has improved in recent
years, disparity in outcomes between African American
(AA) and Caucasian (CA) patients persists [1]. This may
be due to a variety of factors, such as socioeconomic fac-
tors influencing access to good quality care, differences
in screening participation, or tumor biology [2–5].
The Oncotype DX® Colon Cancer Assay (12-gene
assay, Genomic Health, Inc., Redwood City, California)
is a 12-gene RT-PCR based test that yields a Recurrence
Score® result that has been clinically validated to predict
the probability of recurrence following resection of stage
II and stage III colon cancer [6–8]. The 12 genes mea-
sured consist of 7 cancer-related genes, which include 3
cell cycle genes (MK167, MYBL2, and MYC), 3 stromal
genes (BGN, INHBA and FAP), and an early response
gene (GADD45B), and 5 reference normalization genes.
The Recurrence Score result (ranging from 0 to 100 with
lower values representing lower risk of recurrence) is de-
rived from RNA expression levels of these genes as deter-
mined by RT-PCR in formalin-fixed paraffin-embedded
(FFPE) tumor tissue using a quantitative algorithm. The
assay has been shown to add significant information be-
yond conventional clinical and pathologic factors regard-
ing the risk of recurrence and has been shown to be
clinically valid in multiple studies [6–8].
The distribution of Recurrence Score® results and as-
sociated gene expression profiles based on race/ethnicity
have not been previously assessed. We used the 12-gene
assay as a measure of gene expression activity to evalu-
ate possible biological differences between AA and CA
patients with resected stage II colon cancer.
Methods
Patients with resected stage II colon cancer and with ar-
chived tumor tissue were identified from tumor regis-
tries at four institutions (University of Arkansas for
Medical Sciences, Little Rock, AR; Central Arkansas Vet-
erans Healthcare System, Little Rock, AR; University of
Tennessee Cancer Institute, Memphis, TN; and the Uni-
versity of Alabama at Birmingham, Birmingham, AL). In-
stitutional Review Board approval was obtained from the
respective institutions. Demographic and clinical data, in-
cluding pathologic stage, was obtained by manual chart
review. Two hundred ninety three stage II colon cancer
patients, matched for the year of diagnosis, age, and sex,
were selected for the study. Race/ethnicity was self-
reported. Patients with rectal cancer and those with syn-
chronous tumors were excluded from the study. Paraffin
blocks or unstained sections on slides were obtained for
the selected patients. After verification of the diagnosis
and stage by an independent pathologist, the 12-gene
assay and mismatch repair status (MMR) by immunohis-
tochemistry for MLH1 and MSH2 were performed on
these samples at the Genomic Health laboratory.
Statistical methods
Primary analysis
To address the primary objective of the study, the
distributions of the Recurrence Score results for AA
and CA patients were compared. Specifically, t-tests
for two independent samples were used to determine
if there were significant differences between the Recur-
rence Score results and the expression of individual genes
in the two patient groups. If the normality assumption of
the distributions of the Recurrence Score results was
found to be invalid, a nonparametric Wilcoxon rank-sum
test was used. In addition, the Recurrence Score distribu-
tions by race were summarized using histograms and de-
scriptive statistics, such as means, medians, standard
deviations, and ranges. Similar analyses were carried out
to compare the expression levels of gene groups and indi-
vidual genes within the 12-gene assay between the two pa-
tient groups.
Secondary analyses
We compared the distribution of demographic and
pathology variables between AA and CA patients using
Chi-square tests for categorical variables and two-sided
t-tests for continuous variables. We also compared the
distributions of the Recurrence Score results, gene groups
and individual genes between the two patient groups,
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controlling for demographic and pathologic characteris-
tics. We used multiple linear regression models to evalu-
ate the relationships of the continuous Recurrence Score
value, gene groups, and individual genes to relevant demo-
graphic and pathologic covariates, including race, gender,
age at surgery, number of nodes examined, pathologic T
stage, MMR status, and lymphatic vascular invasion (LVI).
All tests of hypotheses were conducted at a two-sided
alpha level of 0.05 unless otherwise noted. In this
exploratory study, we have made no adjustments for
multiple comparisons. All analyses were conducted with
SAS 9.3 (SAS Institute, Cary, NC).
Results
Stage II colon cancer patients (n = 293) were selected
from tumor registries of four institutions (Fig. 1).
Forty patients were excluded from analysis at path-
ology review (24 with insufficient or no invasive can-
cer, 5 with rectal cancer, 4 with no lymph node data,
2 with appendicular cancers and 5 for other reasons).
Six patients were excluded due to laboratory failures
(4 for insufficient RNA and 2 for poor quantitative
PCR quality), and 3 patients were excluded due to
missing MMR testing results. The remaining 244
samples (from 122 AA and 122 CA patients) were
used in the analysis. The racial distribution of pa-
tients from each institution is listed in Fig. 1.
In the cohort of 244 patients, there were 118 women
(63 AA, 55 CA) and 126 men (59 AA, 67 CA) (Table 1).
The median age at surgery was 66 years (range 35–88
years) for AA patients, and 68 years (range 40–97 years)
for CA patients. Surgery was performed before the
year 2000 in 31 % of AA and CA patients, from 2000
to 2009 in 40 % of AA and 49 % of CA patients, and
from 2010 onwards in 29 % of AA and 20 % of CA
patients. Table 1 shows the distribution of the demo-
graphic, clinical, and pathological characteristics of
the patients eligible for analysis. Age, gender, year
of surgery, pathologic stage, tumor location, number
of nodes examined, LVI, and MMR status were not
significantly different between the two racial groups
as determined by Chi-square tests.
The mean Recurrence Score result was 27.9 ± 12.8 for
the AA group and 28.0 ± 11.8 for the CA group and was
not significantly different between groups (p = 0.93)
(Fig. 2). The proportion of patients with a high Recur-
rence Score result (≥41) was similar between the groups:
17/122 (14 %) for AA patients and 15/122 (12 %) for CA
patients (Fig. 3). None of the gene expression variables,
either single genes or gene groups (Cell Cycle group,
Stromal group, BGN, FAP, INHBA, Ki67, MYBL2,
C-MYC, and GADD45B) was significantly different
between the racial groups (p > 0.05 for all individual
genes and gene groups) (Fig. 4).
Linear regression modeling of Recurrence Score result,
gene groups, and individual genes with the explanatory
variables including race, clinical covariates, and patho-
logical covariates (including number of nodes examined,
Fig. 1 CONSORT diagram for the study. Study cohort of subjects selected for the study after exclusion of those who did not meet the
selection criteria. The analysis was based on 244 samples (122 Caucasian patients and 122 African-American patients). IHC: immunohistochemistry;
U Tennessee: University of Tennessee; UAB: University of Alabama Birmingham; UAMS: University of Arkansas for Medical Sciences; VA: Central Arkansas
Veterans Healthcare System
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pathologic T stage, tumor grade, MMR status and LVI
status) revealed no statistically significant association with
patient race (data not shown).
Discussion
Colorectal cancer is the third most common cancer in
men and women in the United States and has the third
highest mortality rate in both genders [1]. Relative to
CA patients, AA patients with colorectal cancer have a
higher incidence, higher mortality, and worse stage-
specific outcomes [1, 9]. The reasons for these disparities
are not well understood. The recent improvement in
survival of patients with colorectal cancer across all
stages has not been seen equally in AA and CA patients:
the overall mortality rate has steadily abated in the last
three decades, but the decline is less pronounced among
AA compared to CA populations [1, 4]. The mortality
rate among AA populations with colorectal cancer at all
stages is in dispute, with some studies showing worse
rates among AA patients with all stages, including early
stage disease [10, 11] while others show the trend only
for those with advanced stage disease [4, 9].
The higher colorectal cancer incidence and mortality
rates among AA have been attributed to differences in
socioeconomic status leading to lack of access to health-
care, although this has been disputed by others [2, 12].
Lack of access to healthcare, resulting in lower rates of
screening and more advanced stage at presentation and
consequently higher mortality, has been noted for the
AA population [12, 13]. In Medicare beneficiaries, there
is evidence for a difference in the treatment received for
colon cancer [13]; for younger populations, there is also
evidence of lower utilization of available treatment with
chemotherapy and radiation among AAs [2, 14]. In con-
trast, studies of the Veterans Affairs Health Care Sys-
tems did not find a statistical difference in overall
survival between AA and CA patients with colorectal
carcinoma and suggested that uniform treatment of their
patient population may be the reason for the lack of a
difference in survival [15, 16]. Albain and colleagues re-
ported that in prospective SWOG studies there was no
difference in outcomes between AA and CA patients
with respect to colon cancer, although AA patients with
breast, prostate, or ovarian cancers had worse overall
survival than CA patients; however, the small sample
size and restriction of analysis to only those who were
receiving adjuvant chemotherapy may have played a role
in the differential results for colon cancer versus other
tumor types [17].
Objective clinical factors have also been examined to
identify underlying reasons for the racial disparity. A
retrospective analysis of patients with colon cancer not
receiving chemotherapy showed a higher mortality for
AA subjects [10]. The difference in disease progression
and worse mortality may be attributed to variations in
tumor pathobiology in patients of different race and eth-
nicity [18, 19]. Several studies [5, 11], including a study
conducted by University of Alabama, Birmingham inves-
tigators found that, although there was no difference in
the distribution of tumor grade between AA and CA
colon cancer patients, AAs with high-grade (poorly dif-
ferentiated) tumors were at three times higher risk of
dying of colorectal cancer as CA patients even after con-
trolling for treatment and prognostic factors [20].
This is the first study to compare the 12-gene assay in
colon cancer among AA and CA patients. This assay has
been validated to predict the recurrence rate in patients
with resected stage II colon cancer, whether treated with
surgery alone or with surgery followed by adjuvant
chemotherapy. We compared the Recurrence Score
Table 1 Demographic and clinical characteristics
Characteristics African American (AA) Caucasian (CA)
Age at Surgery (Yrs.)
Median (Range) 66 (35, 88) 68 (40, 97)
IQR (1st quartile, 3rd quartile) 21 (55–76) 20 (57–77)
Gender
Female (n = 118) 63 (51.6 %) 55 (45.1 %)
Male (n = 126) 59 (48.4 %) 67 (54.9 %)
Surgery Year
<2000 38 (31.2 %) 38 (31.2 %)
≥2000 and <2010 49 (40.2 %) 60 (49.2 %)
≥2010 35 (28.7 %) 24 (19.7 %)
Number of Nodes Examined
Median (Range) 15 (1, 52) 17 (1, 50)
IQR (1st quartile, 3rd quartile) 14 (9, 23) 15 (10, 25)
Tumor Location
Ascending (Ascending, Cecum,
Hepatic flexure, Transverse)
71 (58.2 %) 72 (59.0 %)
Descending (Descending,
Sigmoid, Splenic flexure)
45 (36.9 %) 46 (37.7 %)
Colon NOS 6 (4.9 %) 4 (3.3 %)
T Stage
T3 107 (87.7 %) 109 (89.3 %)
T4 15 (12.3 %) 13 (10.7 %)
MMR Status
Deficient 11 (9.0 %) 21 (17.2 %)
Proficient 111 (91.0 %) 101 (82.8 %)
Lympho-vascular Invasion
Yes 7 (5.7 %) 6 (4.9 %)
No 95 (77.9 %) 97 (79.5 %)
Not Reported 20 (16.4 %) 19 (15.6 %)
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results of AA and CA patients who otherwise showed
no differences in demographic or clinical factors. Al-
though the number of genes assessed by the Oncotype
DX assay is limited in number, the genes are known to
be involved in cancer biology, therefore, the assay repre-
sents a useful, although not comprehensive, probe into
the biology of these tumors. Among both AA and CA
patients, there was a similar distribution of Recurrence
Score results and equal numbers of subjects in both
groups had high Recurrence Score results ≥41. The year
of diagnosis was matched for the two groups to balance
for any inequality in the number of lymph nodes har-
vested due to the introduction of new standards [21].
We did not exclude patients with fewer than 12 nodes
examined because the aim of the study was to evaluate
the expression of the genes underlying the biology of
colon tumors in AA and CA patients, and not to evalu-
ate the risk of recurrence. None of the gene expression
variables, either gene groups or single genes (cell cycle
group, stromal group, BGN1, FAP, INHBA1, Ki67,
MYBL2, cMYC, and GADD45B), was significantly differ-
ent between the patient groups.
A limitation of this study is that the assessment of
genes was limited to those represented by the 12-gene
assay. Accordingly, we cannot rule out the possibility of
other underlying differences in tumor biology and mo-
lecular profiles between AA and CA patients. Further, as
we did not have access to long-term clinical outcomes
for patients in this study, we were unable to assess
whether similarities in gene expression profiles for AA
and CA patients are associated with similar clinical out-
comes. Finally, although the AA and CA cohorts were
matched based on year of diagnosis, age, and sex, the
retrospective nature of this study does not preclude
other potential sources of selection bias.
Conclusion
The distribution of Recurrence Score results, gene ex-
pression levels of gene groups and individual genes were
not significantly different between AA and CA patients;
Fig. 2 The distribution of Recurrence Score results for African-American patients and Caucasian patients. The number of patients with a given Recurrence
Score result is displayed on the vertical axis; the Recurrence Score values are displayed on the horizontal axis. The mean, SD, median, and range
of the Recurrence Score result are inset in each graph. Panel a: display of the Recurrence Score results for AA patients (n = 122). Panel b: display of the
Recurrence Score results for CA patients (n = 122). The mean Recurrence Score result for African-American patients (27.9 ± 12.8) was not
statistically different from that of Caucasian patients (28.1 ± 11.8). The vertical line at 41 represents the cutoff for the high Recurrence
Score risk group [6]. SD: standard deviation; AA: African-American; CA: Caucasian
Fig. 3 Recurrence Score result display by high recurrence risk cut off.
The Recurrence Score result for each patient is displayed as a circle by
ethnicity group. The Recurrence Score results >41 are colored red. The
proportion of patients with high Recurrence Score values (≥41) was
similar between the patient groups (17/122 African-American patients;
15/122 Caucasian patients)
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suggesting tumor biology, as measured by the 12-gene
assay, did not differ between patient groups.
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